ارتباط سطح سرمی پپتید ناتریوارتیک مغزی و اینترلوکین 6 با کیفیت زندگی در بیماران COPD

Title

The Correlation of Serum Brain Natriuretic Peptide and Interleukin-6 with Quality of Life Using Chronic Obstructive Pulmonary Disease Assessment Test

English Abstract

Objective: The aim of this study was to determine the levels of serum pro-brain natriuretic peptide (pro-BNP) and interleukin (IL)-6 in patients with stable chronic obstructive pulmonary disease (COPD) and to correlate these markers with health-related quality of life using COPD assessment test (CAT). Materials and Method: Serum pro-BNP and IL-6 levels were measured in 82 patients with stable COPD. Serum pro-BNP and serum IL-6 levels, pulmonary function, and oxygen saturation (Spo2) were measured according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage and CAT score. Also, the associations of both pro-BNP and IL-6 with clinical parameters of patients were tested. Results: The serum levels of IL-6 (7.57 (5-11.16) pg/ml) and pro- BNP (120.55 (92.89-144.20) pg/ml) were higher with enhancing disease severity based on the GOLD classification (p=0.034 and p=0.068, respectively). Also, that serum levels of pro-BNP (120.55 (89.50-147.90) pg/ml) and IL-6 (6.68 (4.40-11.97) pg/ml) were increased in patients with high CAT scores (p=0.004 and p=0.017, respectively). There was a significant positive correlation between plasma pro-BNP and IL-6 levels (r= 0.332, p=0.002). Conclusion: The results demonstrated that with increased severity of obstruction based on the GOLD criteria both IL-6 and pro-BNP were elevated. This increase in inflammatory markers was associated with reduced quality of life and severity of hypoxia. These findings indicated that lowering IL-6 and pro-BNP could be useful in the management of COPD patients.

Document Downloads